placeholder image
N. P. Klein All authors
About
Publications While At HealthPartners
selected publications
Journal Article
  • 18 Years - VISION and IVY Networks, September 2023-January 2024
    MMWR: Morbidity and Mortality Weekly Report. 2024
  • COVID-19 vaccination coverage and factors associated with vaccine uptake among people with HIV
    JAMA network open. 2024
  • Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023
    Clinical Infectious Diseases. 2024
  • Coronavirus disease 2019 (COVID-19) vaccination and stillbirth in the Vaccine Safety Datalink
    Obstetrics and Gynecology. 2024
  • Effectiveness of the original monovalent and bivalent COVID-19 vaccines against COVID-19-associated emergency department and urgent care encounters in pregnant persons who were not immunocompromised: VISION Network, June 2022-August 2023
    Open forum infectious diseases. 2024
  • Influenza vaccination accuracy among adults: self-report compared with electronic health record data
    Vaccine. 2024
  • Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023
    Journal of Infectious Diseases. 2024
  • Interim estimates of 2023-24 seasonal influenza vaccine effectiveness - United States
    MMWR: Morbidity and Mortality Weekly Report. 2024
  • JYNNEOS vaccine safety surveillance in the vaccine safety datalink during the 2022 mpox outbreak in the United States
    Infection. 2024
  • Lack of evidence for vaccine-associated enhanced disease from COVID-19 vaccines among adults in the Vaccine Safety Datalink
    Pharmacoepidemiology and Drug Safety. 2024
  • Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis
    Lancet (London, England). 2024
  • Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders
    Influenza and other respiratory viruses. 2024
  • Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network
    Clinical Infectious Diseases. 2024
  • A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination
    Vaccine. 2023
  • Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data
    American Journal of Epidemiology. 2023
  • Association between aluminum exposure from vaccines before age 24 months and persistent asthma at age 24 to 59 months
    Academic Pediatrics. 2023
  • COVID-19 booster vaccination in early pregnancy and surveillance for spontaneous abortion
    JAMA network open. 2023
  • COVID-19 vaccine safety surveillance in early pregnancy in the United States: design factors affecting the association between vaccine and spontaneous abortion
    American Journal of Epidemiology. 2023
  • Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents
    Pediatrics. 2023
  • Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021
    Vaccine. 2023
  • Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023
    American Journal of Transplantation. 2023
  • Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods
    JAMA network open. 2023
  • Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design
    Vaccine. 2023
  • Influenza vaccination among pregnant people before and during the coronavirus disease 2019 (COVID-19) pandemic
    Obstetrics and Gynecology. 2023
  • Influenza vaccination among pregnant women: self-report compared with vaccination data from electronic health records, 2018-2020 influenza seasons
    Public Health Reports. 2023
  • Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022
    Journal of Infectious Diseases. 2023
  • Safety of measles, mumps, and rubella vaccine in adolescents and adults in the Vaccine Safety Datalink
    Vaccine. 2023
  • Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink
    Vaccine. 2023
  • Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
    Vaccine. 2023
  • Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes
    Vaccine. 2023
  • Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network
    Journal of Infectious Diseases. 2023
  • Association of the COVID-19 pandemic with routine childhood vaccination rates and proportion up to date with vaccinations across 8 US health systems in the Vaccine Safety Datalink
    JAMA pediatrics. 2022
  • Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021
    American Journal of Transplantation. 2022
  • Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States
    JAMA network open. 2022
  • Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the Vaccine Safety Datalink
    JAMA network open. 2022
  • Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
    Vaccine. 2022
  • Safety of COVID-19 vaccination in United States children ages 5 to 11 years
    Pediatrics. 2022
  • Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero
    Pediatrics. 2022
  • Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
    BMJ (Clinical research ed.). 2022
  • Association of inadvertent 9-valent human papillomavirus vaccine in pregnancy with spontaneous abortion and adverse birth outcomes
    JAMA network open. 2021
  • COVID-19 vaccination coverage among insured persons aged ≥16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Developing algorithms for identifying major structural birth defects using automated electronic health data
    Pharmacoepidemiology and Drug Safety. 2021
  • Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings
    New England Journal of Medicine. 2021
  • Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination
    Vaccine. 2021
  • Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance - nine states, June-August 2021
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Surveillance for adverse events after COVID-19 mRNA vaccination
    JAMA. 2021
  • Temporal trends in undervaccination: a population-based cohort study
    American Journal of Preventive Medicine. 2021
  • The childhood vaccination schedule and the lack of association with type 1 diabetes
    Pediatrics. 2021
  • Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination
    Therapeutic advances in drug safety. 2021
  • Association between rotavirus vaccination and type 1 diabetes in children
    JAMA pediatrics. 2020
  • Evaluating the association of stillbirths after maternal vaccination in the Vaccine Safety Datalink
    Obstetrics and Gynecology. 2020
  • SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics - eight U.S. health care centers, March 1-May 30, 2020
    MMWR: Morbidity and Mortality Weekly Report. 2020
  • Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders
    Vaccine. 2019
  • Uptake and safety of hepatitis A vaccination during pregnancy: a Vaccine Safety Datalink study
    Vaccine. 2019
  • Infant hospitalizations and mortality after maternal vaccination
    Pediatrics. 2018
  • Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy
    Obstetrics and Gynecology. 2018
  • Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents
    Pharmacoepidemiology and Drug Safety. 2018
  • The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: a Vaccine Safety Datalink study
    Pharmacoepidemiology and Drug Safety. 2018
  • Uptake and safety of Hepatitis B vaccination during pregnancy: a Vaccine Safety Datalink study
    Vaccine. 2018
  • Congenital microcephaly: case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation
    Vaccine. 2017
  • Febrile seizure risk after vaccination in children one to five months of age
    Pediatric Neurology. 2017
  • First trimester influenza vaccination and risks for major structural birth defects in offspring
    Journal of Pediatrics. 2017
  • Identifying birth defects in automated data sources in the Vaccine Safety Datalink
    Pharmacoepidemiology and Drug Safety. 2017
  • Maternal Tdap vaccination and risk of infant morbidity
    Vaccine. 2017
  • Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy
    Obstetrics and Gynecology. 2017
  • Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults
    BMC Pulmonary Medicine. 2017
  • Febrile seizure risk after vaccination in children 6 to 23 months
    Pediatrics. 2016
  • Influenza vaccination during pregnancy: influenza seasons 2002-2012, Vaccine Safety Datalink
    American Journal of Preventive Medicine. 2016
  • Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013
    Vaccine. 2016
  • Risk of anaphylaxis after vaccination in children and adults
    Journal of Allergy and Clinical Immunology. 2016
  • Risk of preterm or small-for-gestational-age birth after influenza vaccination during pregnancy: caveats when conducting retrospective observational studies
    American Journal of Epidemiology. 2016
  • Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations
    JAMA. 2015
  • Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006
    Vaccine. 2015
  • Safety of measles-containing vaccines in 1-year-old children
    Pediatrics. 2015
  • Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy
    Obstetrics and Gynecology. 2015
  • Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes
    JAMA. 2014
  • Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink Sites
    Preventive Medicine. 2014
  • Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine
    Vaccine. 2014
  • Vaccinations given during pregnancy, 2002-2009: a descriptive study
    American Journal of Preventive Medicine. 2014
  • Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children
    JAMA pediatrics. 2013
  • Measles-containing vaccines and febrile seizures in children age 4 to 6 years
    Pediatrics. 2012
  • Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age
    Vaccine. 2011
  • Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink
    Archives of Pediatrics and Adolescent Medicine. 2011
  • Lack of association between acellular pertussis vaccine and seizures in early childhood
    Pediatrics. 2010
  • Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
    Pediatrics. 2010
  • Varicella vaccination and ischemic stroke in children: is there an association?
    Pediatrics. 2009
  • Contact
    full name
  • N. P. Klein
  • Quick Info
     
    Collaboration